888216-25-9

Basic information

• Product Name: Ganetespib
• Synonyms: 5-[2,4-Dihydroxy-5-(1-methylethyl)phenyl]-2,4-dihydro-4-(1-methyl-1H-indol-5-yl)-3H-1,2,4-triazol-3-one;Ganetespib (STA-9090);3H-1,2,4-Triazol-3-one, 5-[2,4-dihydroxy-5-(1-Methylethyl)phenyl]-2,4-dihydro-4-(1-Methyl-1H-indol-5-yl)-;SAT9090;2,4-Dihydro-5-[2,4-dihydroxy-5-isopropylphenyl]-4-(1-methyl-1H-indol-5-yl)-3H-1,2,4-triazol-3-one;5-{1,5-Dihydro-3-[2,4-dihydroxy-5-(prop-2-yl)phenyl]-5-oxo-4H-1,2,4-triazol-4-yl}-1-methyl-1H-indole, 4-[4,5-Dihydro-4-(1-methyl-1H-indol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-6-(prop-2-yl)benzene-1,3-di ol;5-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methyl-1H-indol-5-yl)-2H-1,2,4-triazol-3(4H)-one;STA-9090/Ganetespib
• CAS NO: 888216-25-9
• Molecular Formula: C20H20N4O3
• Molecular Weight: 364.3978
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 888216-25-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.39
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (up to at least 25 mg/ml)
• PKA: 7.38±0.20(Predicted)
• Stability: Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: Ganetespib(CAS DataBase Reference)
• NIST Chemistry Reference: Ganetespib(888216-25-9)
• EPA Substance Registry System: Ganetespib(888216-25-9)

Safety Data

• Hazardous Substances Data: 888216-25-9(Hazardous Substances Data)

Usage

Description

Ganetespib is a potent inhibitor of heat shock protein 90 (HSP90) that binds to the N-terminal ATP site, exhibiting significant cytotoxicity against a range of transformed cell lines of both hematologic and solid tumors. It has demonstrated the ability to enhance T-cell-mediated killing of human melanoma cells and potentiate responses to anti-CTLA4 and anti-PD1 therapy by upregulating interferon response genes. Ganetespib has been evaluated in multiple clinical trials for various cancer types.

Uses

Used in Pharmaceutical Industry:
Ganetespib is used as an anticancer agent for its ability to inhibit heat shock protein 90, which plays a crucial role in the survival and proliferation of cancer cells. Its potent cytotoxicity against various transformed cell lines makes it a promising candidate for the treatment of both hematologic and solid tumors.
Used in Immunotherapy:
Ganetespib is used as an immunotherapy enhancer to improve the effectiveness of T-cell-mediated killing of human melanoma cells. It has shown the potential to potentiate responses to anti-CTLA4 and anti-PD1 therapies by upregulating interferon response genes, which can lead to better clinical outcomes for cancer patients.
Used in Clinical Research:
Ganetespib is utilized in multiple clinical trials to evaluate its safety, efficacy, and potential as a treatment option for various cancer types. These trials aim to determine the optimal dosing, administration, and combination therapies that can maximize the benefits of Ganetespib in cancer treatment.

Upstream product

• 959466-51-4 2,4-bis(benzyloxy)-5-isopropylbenzaldehyde 
• 958888-27-2 5-isopropyl-2,4-dihydroxy benzaldehyde 
• 23504-03-2 2,4-dihydroxy-1-isopropylbenzene 
• 958888-24-9 N-(1-methyl-1H-indol-5-yl)hydrazinecarboxamide 
• 152239-62-8 phenyl N-(1-Methyl-1H-indol-5-yl)-carbamate 
• 102308-97-4 1-methyl-1H-indol-5-amine 
• 29906-67-0 1-methyl-5-nitro-1H-indole 
• 6146-52-7 5-nitroindole 
• 958888-26-1 C₃₄H₃₂N₄O₃ 

Relevant articles and documents

COMBINATION THERAPY FOR TREATING CANCER

A method of treating cancer comprising administering an effective amount of each of a chemotherapeutic agent and an Hsp90 inhibitor, either separately or as a covalent conjugate of the two, to provide a combination therapy having an enhanced therapeutic e